SCHEMBL14404264

SCHEMBL14404264

CCCCNS(=O)(=O)c1ccccc1-c1ccc(C(=O)CI)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.53
CA9 Q16790 3/20 0.53
RECQL P46063 1/20 0.45
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
F2 P00734 1/20 0.42
F10 P00742 1/20 0.42
PRSS1 P07477 1/20 0.42
FEN1 P39748 6/20 0.41
ALOX5AP P20292 5/20 0.41
AGTR1 P30556 2/20 0.41
AGTR2 P50052 1/20 0.41
BRD4 O60885 2/20 0.40
PTGER1 P34995 1/20 0.40
PTGER3 P43115 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14366117 0.85 CA12 (0.55) CA12CA9RECQLMMP1MMP2
SCHEMBL3632239 0.82 CA12 (0.62) CA12CA9RECQLBRD4MEN1
SCHEMBL10145901 0.80 CA12 (0.53) CA12CA9RECQLMMP1MMP2
SCHEMBL12496885 0.77 RECQL (0.65) CA12CA9RECQLBRD4MEN1
SCHEMBL14404265 0.73 L3MBTL1 (0.54) MEN1TSHRKMT2ATDP1
SCHEMBL12132460 0.73 CA12 (0.46) CA12CA9RECQLMMP1MMP2
SCHEMBL12132453 0.72 ALDH1A1 (0.52) CA12CA9MMP1MMP2MMP9
SCHEMBL9738489 0.70 CA12 (0.66) CA12CA9RECQLBRD4MEN1
SCHEMBL3978111 0.70 CA12 (0.61) CA12CA9RECQLBRD4MEN1
SCHEMBL8062917 0.70 CA9 (0.74) CA12CA9RECQLBRD4HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285565-B2 Benzamides and related inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-10-23 US disclosed
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility MILLENNIUM PHARMACEUTICALS, INC. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility F2, TFPI, PLG CA12 2610/4885CA9 2286/4885RECQL 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.